drugset / Trial / NCT00493051

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051 ↗

Phase 2 Completed 124 enrolled Tissue Repair Company Cardium Therapeutics · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of one or two applications of topically applied GAM501 (Ad5PDGF-B/Bovine Type I Collagen Gel) in subjects ≥ 18 years old with non-healing diabetic foot ulcers. Approximately 210 adult subjects with Type I or Type II diabetes mellitus will be enrolled at approximately 30 investigational sites in the United States.

Timeline

Start
2007-11
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator GAM501 Unknown — Topical

Indications

No indication recorded.